IFUL Insightful Corp (MM)

Insightful Corporation (NASDAQ:IFUL), a leading provider of predictive analytics and reporting solutions, announced today that GlaxoSmithKline (GSK), one of the world�s leading research-based pharmaceutical and healthcare companies, is using a clinical graphics solution developed by Insightful and S-PLUS�, Insightful�s software platform for statistical data analysis and predictive analytics, to speed the design, analysis, and reporting of clinical trial data. "We are committed to this S-PLUS graphics solution to assist our statisticians and scientists in understanding our data, and to improve the communication of results," said Dr. Roger F. Liddle, Vice President of Discovery Biometrics at GSK and sponsor of GSK�s clinical graphics initiative. �As of end of 2007, we have over 200 statisticians, programmers and epidemiologists trained. We are seeing significant uptake of the S-PLUS graphics solution, with the majority of users finding it an easy way to produce high quality graphs. The clinical graphics our staff are producing are being used by GSK statisticians, clinicians, and publishing staff in several critical areas, including data analysis, presentation, submission, and publication.� Insightful�s clinical graphics solutions are designed to enable effective communication of clinical data in journals, presentations, and regulatory submissions through point-and-click creation of advanced graphics and seamless integration with existing exploratory, presentation, and production reporting environments. Important benefits of these clinical graphics solutions include the ease of use for those without specialized programming skills and streamlined graphics production across all clinical and reporting areas, minimizing the time and cost incurred by expensive and scarce statistical programming resources. GSK is employing Insightful�s S-PLUS platform and advanced statistical graphics libraries, including Trellis� technology and a comprehensive graphics taxonomy collection. These libraries deliver industry-standard graphics for interpreting and communicating information in clinical data. "GSK is a world-recognized leader in the use of statistical graphics for analysis, presentation, and communication of information in clinical data," said Jeff Coombs, president and CEO of Insightful. "The clinical graphics solution that we built for GSK on top of our S-PLUS platform provides them with an integrated solution for extracting and communicating information in clinical data across their organization and to their clinical and regulatory partners. We are pleased to have the opportunity to assist GSK in this core function of their business." ABOUT INSIGHTFUL Insightful Corporation (NASDAQ:IFUL) is a provider of predictive analytics and reporting solutions. Insightful products S-PLUS�, Insightful Miner� and S-PLUS� Enterprise Server allow companies to perform sophisticated statistical data analysis and data mining and create high-quality graphics and reports. Insightful has been delivering industry-leading, high-ROI solutions to thousands of companies in financial services, life sciences, telecommunications, and manufacturing, plus government and research institutions, for 20 years. Headquartered in Seattle, Insightful has offices in New York, North Carolina, the United Kingdom, Switzerland, France and Hong Kong, with distributors around the world. For more information, visit www.insightful.com, email info@insightful.com or call 1-800-569-0123. Note to Investors � Forward Looking Statements This press release contains forward-looking statements, including statements about the expected value of Insightful�s clinical graphics solutions to GSK and other customers. Forward-looking statements are based on the judgment and opinions of management at the time the statements are made. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from those expressed or implied by the forward-looking statements for a number of reasons, including, without limitation, the risk that Insightful�s clinical graphics solutions do not perform as designed and expected or do not achieve market acceptance. More detailed information regarding these and other factors that could affect actual results is set forth in our filings with the Securities and Exchange Commission, including our most recent report on Form 10-QSB. You should not unduly rely on these forward-looking statements, which apply only as of the date of this release. We undertake no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of anticipated events.